

HIV Incidence in Placebo-Controlled Prevention Trials

Trial	Px Modality	Years	Location	Population	Incidence
HVTN 706/Mosaico	Vaccine	2019-23	United States of America, Argentina, Italy, Mexico, Peru, Poland, Spain	Cisgender men and transgender individuals who have sex with cisgender men and/or transgender Individuals	4.1
HVTN 705/Imbokodo	Vaccine	2017-22	Malawi, Mozambique, South Africa, Zambia, Zimbabwe	Cisgender women	4.3
HVTN 704 /HPTN 085/ AMP	Antibody	2017-20	United States of America, Brazil, Peru, Switzerland	Cisgender men and transgender individuals who have sex with cisgender men	3.0
HVTN 703/HPTN 081/AMP	Antibody	2016-21	Botswana, Kenya, Malawi, Mozambique, South Africa, Tanzania, Zimbabwe	Cisgender women	3.1
HVTN 702/Uhambo	Vaccine	2016-20	South Africa	Women and men	4.2 (female), 1.2 (male)
ECHO	Multiple contraceptives	2015-18	Eswatini, Kenya, South Africa, Zambia	Cisgender women	4.2, 3.9, 3.3
ASPIRE	Vaginal ring	2012-15	Malawi, South Africa, Uganda, Zimbabwe	Cisgender women	4.5
Ring Study	Vaginal ring	2012-15	South Africa, Uganda	Cisgender women	6.1
FACTS 001	Microbicide gel	2011-14	South Africa	Cisgender women	4.0
VOICE	Microbicide gel and oral PrEP	2009-13	South Africa, Uganda, Zimbabwe	Cisgender women	4.2
CAP 004	Vaginal ring	2007-10	South Africa	Cisgender women	9.1
HPTN 035	Microbicide gel	2005-09	Malawi, South Africa, Zambia, Zimbabwe	Cisgender women	3.9
MDP 301	Microbicide gel	2005-08	South Africa, Tanzania, Uganda, Zambia	Cisgender women	4.2
MIRA	Vaginal diaphragm	2003-07	South Africa, Zimbabwe	Cisgender women	3.9